Member Info for Kong1

Where is our saviour.

The man that has done 50 hours of intense research .

The man that can email the Nomads. And put demands on the company otherwise he will bring it down.

Are you responsible for this mr Beekeeper ?

What a deluded arrogant tool

Hi Buenavista

Lol sorry about that my fat fingers pushed wrong thread by mistake

However we look at all this, bloody exciting times ahead I say

Buenavista

I think it’s safe to say that a greater percentage of the doseage of AVA6000 is left in the tumour than the standard form of doxorubicin administered by standard of care today .

So by giving the same amount of AVA6000 as of the standard amount of dox today we can give the patient many many more cycles and within days between each cycle rather than weeks, leaving the cancer no chance of recovery, also knowing each cycle will leave a far greater percentage of dox in the tumour .

The safety level we have witnessed so far in the first phase

Will become standard of care over night once we have the rubber stamp.

Avacta now know they have the product, all they need to do know is to find the optimum dose coupled with the number of cycles.

3 weeks is the time between doses , using stand dox as it is today.

I’m hoping that in the trial P1b. That we shorten the dosing interval down to one week or even less eventually.

Standard of care now allows the body to recover in the 3 week interval. Also no doubt the cancer recovers too.

I’m hoping by shortening the dosing interval. The cancer will struggle to recover giving AVA6000 even more therapeutic help.

Looking forward to the phase 1b study and to see the different number of options.

Kong

It doesn’t matter if it only works at the same level therapeutically as standard dox.

Because the safety and tolerability far exceeds standard of care now .

But we do know it works better as patients are still recieving treatment and their cancer is in remission

Ostrich

Avacta turned up with a Paradox shotgun / rifle. Holland & Holland produced them. Ive seen a few myself and do you know what ?

they do everything that it says on the Tin.

Accurate as a rifle and great as a shotgun.

And thats what Avacta has, The ultimate weapon !!!

My feeling is, that whatever cohort the patients were on, i`d say the same dosing will be given as this would give Avacta more positive feed back than simply altering the doseage.

By altering the doseage would complicate and give wrong readings.

everything needs to stay linear.

kong

Beunavista

Apparently £14b was wiped off AZ share value.

Just think they could have given us that money and got a drug that actually works !

I’ll send an email to AS asking if he can go and give them a hand !!

Ive not seen many messages on this subject but, it was discussed in AGM Q&A meeting.

Avacta has taken the AVA6000 route for several reasons.

I think P1a is now a given. All the data is extremely positive, hence why we have been given 3 more cohorts.

Phase 1b will give us an indication of efficay, at some point half way through the trial AS mentioned they will know how well its working.

At this point many companies will want to partner up, to use the patent application of AVA for thier own extremely toxic chemos that work.

But because of the high toxicity, the companies can not use their drug, or in extremely small doses.

The market for Dox is £1.4b, then you have a bigger market for AVA3996 and then several more lines that Avacta are potentially pursuing.

Then like I mentioned, when AVA6000 is a proven force, many other companies will want their drugs to market.

So the market will not be £2-4b per annum to Avacta, in several years time it will be many multiples of this.

The concept and potential of any takeover by any company is not just the value of AVA6000, but many many more applications.

Any takeover will have to factor all of these possibilites into a figure, one which could be unthinkable.

life changing for many people, both medical and finiancial

As I see it.

The news has been released beyond our expectations.

The only news we need now that will put serous icing on the cake is, now many doses and how much amounts some of these patients have had, and to what levels the tumours have receded to.

Also whether the patients are still receiving treatments.

This information is what is needed now.

I’m hoping AS can shed some light on these questions at the AGM

£27m in the bank should see them through to oct next year.

By then all the info needed will be out.

Strong possibility of a takeover.

Chances of another funding round is slim.

Occam

Like grey badger another idiot trying to manipulate the situation.

The value you talk about at the end of jan 22 was for the company in 2021.

RS and tintra has nothing in that year..

All the work, and IP are and was started by tintra from after that trading period.

So stop trying to make out that Tintra is only worth £180,000.

You, grey badger & bee keeper are all deluded

Grey badger

You’ve got everything wrong .

Another armchair director who knows everything. Sell up and move on, obviously this share is not for you

I wonder if the question could be asked at the AGM.

What cohorts have the patients been that is still receiving AVA6000.

How many cycles have they been on, and what total amounts of AVA6000 have they been given so far. ?

The question now is how many other cancer types could AVA6000 used for becsuse before the trials. AVA6000 wasn’t supposed to be beneficial to the patients enrolled.

Will this create a bigger market for the product. ?

PL75

For me anyone with no toxicity in the heart etc should be ok to take more.

Why not ?

Oamot

I totally agree

3 weeks is standard time between each dosing as we speak today.

It appears that very little side affects seem to be observed in patients using AVA600.

So could they administer dosing every 14 days now or even every 7 days .

That would certainly speed things up.

Possibly a question for some to ask at the AGM !

I suspect that the patients still receiving treatments from previous cohorts will be monitored closely and information will be downloaded to give best scenoirio for Next phase.

It’s an unexpected help and insight for team Avacta, to come up with dose levels and application times.

Avacta has made it quite clear that due to minimal side affects. Dosing times could be speeded up.

Patients from previous cohorts not just cohort 5 are still being treated and are improving.

So how many doses have they had ?

All this against tumours that wasn’t going to be effected by doxorubicin.

It now proves that the next trials are going to be fantastic

Remember these trials were supposed to be treating patients with tumours that doxorubicin was not going to be affective against !

And now the patients are still receiving treatments and are getting better.

So when we get to the trials that used patients that have tumours that doxorubicin is effective against .

Well I leave it up to you to figure that one out